Last reviewed · How we verify

Selinexor Tablets — Competitive Intelligence Brief

Selinexor Tablets (Selinexor Tablets) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Selective inhibitor of nuclear export (SINE). Area: Oncology.

phase 3 Selective inhibitor of nuclear export (SINE) XPO1/CRM1 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Selinexor Tablets (Selinexor Tablets) — Chengdu Zenitar Biomedical Technology Co., Ltd. Selinexor is a selective inhibitor of nuclear export (SINE) that blocks XPO1/CRM1, preventing the export of tumor suppressor proteins from the nucleus and leading to their accumulation and activation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Selinexor Tablets TARGET Selinexor Tablets Chengdu Zenitar Biomedical Technology Co., Ltd phase 3 Selective inhibitor of nuclear export (SINE) XPO1/CRM1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Selective inhibitor of nuclear export (SINE) class)

  1. Chengdu Zenitar Biomedical Technology Co., Ltd · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Selinexor Tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/selinexor-tablets. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: